Becton Dickinson and Co (NYSE:BDX) – Jefferies Financial Group cut their Q1 2019 earnings estimates for shares of Becton Dickinson and in a research report issued on Wednesday, November 7th. Jefferies Financial Group analyst B. Couillard now expects that the medical instruments supplier will post earnings per share of $2.58 for the quarter, down from their previous forecast of $2.90. Jefferies Financial Group also issued estimates for Becton Dickinson and’s Q2 2019 earnings at $2.82 EPS and FY2019 earnings at $12.10 EPS.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the consensus estimate of $2.93. The business had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The company’s revenue was up 39.0% compared to the same quarter last year. During the same period last year, the company posted $2.40 EPS.
Shares of BDX traded down $2.87 during trading hours on Friday, hitting $241.61. 6,235 shares of the company were exchanged, compared to its average volume of 1,330,895. The firm has a market cap of $64.40 billion, a PE ratio of 21.95, a P/E/G ratio of 1.44 and a beta of 1.19. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and has a one year low of $209.91 and a one year high of $265.87.
In other news, EVP James C. Lim sold 5,189 shares of the stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $242.36, for a total value of $1,257,606.04. Following the completion of the sale, the executive vice president now owns 13,318 shares in the company, valued at $3,227,750.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Timothy M. Ring sold 42,000 shares of the stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the sale, the director now owns 93,688 shares of the company’s stock, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. 1.00% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acropolis Investment Management LLC purchased a new stake in shares of Becton Dickinson and in the third quarter valued at $101,000. Almanack Investment Partners LLC. purchased a new stake in shares of Becton Dickinson and in the second quarter valued at $105,000. Truvestments Capital LLC purchased a new stake in shares of Becton Dickinson and in the third quarter valued at $105,000. Bartlett & Co. LLC lifted its holdings in shares of Becton Dickinson and by 2,900.0% in the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 435 shares in the last quarter. Finally, Bridgeworth LLC purchased a new stake in shares of Becton Dickinson and during the second quarter worth $131,000. Institutional investors own 92.60% of the company’s stock.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.